Skip to content

Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)

A Study of Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C or Hepatitis B

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00662194
Enrollment
40
Registered
2008-04-21
Start date
2008-04-30
Completion date
2014-10-31
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-hepatitis Co-infection, HIV Infections

Keywords

HIV, HBV, HCV, co-infection, innate immunity

Brief summary

Data from this study will provide the first information how the innate immune system may be altered in HIV-HCV and HIV-HBV co-infected individuals, and describe Toll-like receptor changes with HIV co-infection therapy.

Detailed description

It has been demonstrated that Toll-like receptors (TLR) are involved in viral hepatitis - hepatitis B (HBV), hepatitis C (HCV) - and HIV in the setting of mono-infection. However the role of innate immunity in the pathogenesis of HIV-hepatitis co-infection in both natural and therapy-associated viral clearance remains unclear. The data from this study may reveal patterns which could predict how and when patients spontaneously, and with therapy, resolve HBV or HCV in the setting of co-infection. The aim of the study is to evaluate the activity of innate immunity in different subsets of HIV-infected populations co-infected with chronic hepatitis B and/or C. Our hypothesis is that innate immunity is altered in HIV and hepatitis co-infection and that this differs from both hepatitis and HIV mono-infection. The study is a cross-sectional and longitudinal pilot study of individuals infected with HIV and either HBV or HCV.

Interventions

None listed

Sponsors

Monash Medical Centre
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
Bayside Health
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV and either HBV or HCV co-infection * 18 years and older * able to give informed consent

Exclusion criteria

* HIV-HBV-HCV triple infection

Design outcomes

Primary

MeasureTime frame
TLR change with HIV co-infection therapy6 months

Secondary

MeasureTime frame
TLR change patterns on spontaneously and on treatment resolved HBV or HCV in the co-infected setting6 months

Countries

Australia

Contacts

Primary ContactJennifer Audsley, PhD
jennifer.audsley@med.monash.edu.au+613 99030184

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026